Overexpression of CCDC69 Activates P14/MDM2/p53 Pathway and Confers Cisplatin Sensitivity

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2019 Jan 18

PMID 30651135

Citations 9

Authors

Long Cui

Fang Zhou

Cui Chen

Chi Chiu Wang

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of the study is to explore the relationship between CCDC69 expression and resistance of ovarian cancer cells to cisplatin and reveal the underlying mechanism.

Methods: One hundred thirty five ovarian cancer patients with intact chemo-response information from The Cancer Genome Atlas (TCGA) database were included and analyzed. Stable CCDC69 overexpressing 293 and ovarian cancer A2780 cell lines were established and subjected to examine cell apoptosis and cell cycle distribution using CCK-8 assay and flow cytometry. Cell cycle and apoptosis pathway were evaluated by immunoblots. Stability of p14/MDM2/p53 pathway related proteins were determined by half-life analysis and ubiquitination experiments.

Results: We found that CCDC69 expression was significantly higher in chemo-sensitive groups compared with chemo-resistant groups from TCGA database. High CCDC69 expression was associated longer survival. CCDC69 overexpressing 293 and A2780 cells with wildtype p53 and contributes to cisplatin sensitivity following treatment with cisplatin. We further found over-expression of CCDC69 activated p14/MDM2/p53 pathway. Importantly, we also demonstrated that CCDC69 expression extended p53 and p14 protein half-life and shortened MDM2 protein half-life. Ubiquitination assay revealing a decrease in p14 ubiquitination in CCDC69 over-expression cells comparing to cells expressing empty vector.

Conclusions: It is tempting to conclude that targeting CCDC69 may play a role in cisplatin resistance.

Citing Articles

CDC20 protects the heart from doxorubicin-induced cardiotoxicity by modulating CCDC69 degradation.

Feng Z, Zhang N, Wang L, Guan X, Xie Y, Xia Y Cell Mol Biol Lett. 2025; 30(1):29.

PMID: 40045239 PMC: 11884132. DOI: 10.1186/s11658-025-00708-8.

CCDC69 maintains genome integrity by regulating KIF2C/MCAK depolymerase activity and the stability of the chromosomal passenger complex.

Fesquet D, Rabeharivelo G, van Dijk J, Prigent C, Morin N, Rouquier S Sci Rep. 2024; 14(1):30401.

PMID: 39638803 PMC: 11621681. DOI: 10.1038/s41598-024-81022-9.

High expression of CCDC69 is correlated with immunotherapy response and protective effects on breast cancer.

Wang Z, Ren H, Zhu G, Zhang L, Cao H, Chen B BMC Cancer. 2023; 23(1):974.

PMID: 37828454 PMC: 10571395. DOI: 10.1186/s12885-023-11411-2.

CCDC69 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration.

Yi Y, Xu T, Tan Y, Lv W, Zhao C, Wu M Front Surg. 2022; 9:879921.

PMID: 35910470 PMC: 9334777. DOI: 10.3389/fsurg.2022.879921.

The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance.

Meng Y, Qiu L, Zhang S, Han J Cancer Drug Resist. 2022; 4(2):365-381.

PMID: 35582023 PMC: 9019267. DOI: 10.20517/cdr.2020.115.

References

Ichimura K, Bolin M, Goike H, Schmidt E, Moshref A, Collins V . Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. 2000; 60(2):417-24. View

Wang M, Yip H, Srivatsan E . Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin. Laryngoscope. 2001; 111(6):982-8. DOI: 10.1097/00005537-200106000-00010. View

Nozaki M, Tada M, Kashiwazaki H, Hamou M, Diserens A, Shinohe Y . p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade. Brain Pathol. 2001; 11(3):296-305. PMC: 8098457. DOI: 10.1111/j.1750-3639.2001.tb00400.x. View

Reles A, Wen W, Schmider A, Gee C, Runnebaum I, Kilian U . Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001; 7(10):2984-97. View

Havrilesky L, ALVAREZ A, Whitaker R, Marks J, Berchuck A . Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol Oncol. 2001; 83(3):491-500. DOI: 10.1006/gyno.2001.6464. View

Olivier M, Eeles R, Hollstein M, Khan M, Harris C, Hainaut P . The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002; 19(6):607-14. DOI: 10.1002/humu.10081. View

Weber H, Samuel T, Rauch P, Funk J . Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene. 2002; 21(20):3207-12. DOI: 10.1038/sj.onc.1205429. View

Eymin B, Leduc C, Coll J, Brambilla E, Gazzeri S . p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene. 2003; 22(12):1822-35. DOI: 10.1038/sj.onc.1206303. View

Martin A, Kanetsky P, Amirimani B, Colligon T, Athanasiadis G, Shih H . Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1?. J Med Genet. 2003; 40(4):e34. PMC: 1735423. DOI: 10.1136/jmg.40.4.e34. View

10.

McKenzie P, Danks M, Kriwacki R, Harris L . P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0-G1 cell cycle arrest. Cancer Res. 2003; 63(13):3840-4. View

11.

Culligan K, Tissier A, Britt A . ATR regulates a G2-phase cell-cycle checkpoint in Arabidopsis thaliana. Plant Cell. 2004; 16(5):1091-104. PMC: 423202. DOI: 10.1105/tpc.018903. View

12.

Normand G, Hemmati P, Verdoodt B, Von Haefen C, Wendt J, Guner D . Retracted: p14ARF induces G2 cell cycle arrest in p53- and p21-deficient cells by down-regulating p34cdc2 kinase activity. J Biol Chem. 2004; 280(8):7118-30. DOI: 10.1074/jbc.M412330200. View

13.

Sherr C . Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006; 6(9):663-73. DOI: 10.1038/nrc1954. View

14.

Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian S, Hainaut P . Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28(6):622-9. DOI: 10.1002/humu.20495. View

15.

Krempler A, Deckbar D, Jeggo P, Lobrich M . An imperfect G2M checkpoint contributes to chromosome instability following irradiation of S and G2 phase cells. Cell Cycle. 2007; 6(14):1682-6. DOI: 10.4161/cc.6.14.4480. View

16.

Tothill R, Tinker A, George J, Brown R, Fox S, Lade S . Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008; 14(16):5198-208. DOI: 10.1158/1078-0432.CCR-08-0196. View

17.

Mizuno H, Kitada K, Nakai K, Sarai A . PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009; 2:18. PMC: 2689870. DOI: 10.1186/1755-8794-2-18. View

18.

Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M . Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One. 2010; 5(3):e9615. PMC: 2837379. DOI: 10.1371/journal.pone.0009615. View

19.

Han J, Goldstein L, Hou W, Gastman B, Rabinowich H . Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J Biol Chem. 2010; 285(29):22473-83. PMC: 2903343. DOI: 10.1074/jbc.M109.081042. View

20.

Hemmati P, Muer A, Gillissen B, Overkamp T, Milojkovic A, Wendt J . Systematic genetic dissection of p14ARF-mediated mitochondrial cell death signaling reveals a key role for p21CDKN1 and the BH3-only protein Puma/bbc3. J Mol Med (Berl). 2010; 88(6):609-22. DOI: 10.1007/s00109-010-0606-5. View